GET DAILY SIGNALSWhy Is Azenta (AZTA) Stock Up +19.05% Today?
Key Takeaways
- Sharp rally: AZTA shares jumped roughly 19% to about $48.19, up from a prior close of $40.48.
- Primary catalyst: A fiscal fourth-quarter 2026 earnings and revenue beat, paired with fiscal 2027 guidance that topped consensus.
- Secondary drivers: Double-digit growth in Sample Management Solutions and new gene-synthesis deals with Elegen and SynPlexity.
- Market context: The move extended a post-earnings after-hours surge as the life sciences tools sector drew renewed buying interest.
- What traders are watching: Q1 fiscal 2027 execution, the Multiomics turnaround, and margin expansion progress.
- For deeper detail on valuation, get Price Targets, review Earnings, and check the AI-driven Forecast.
- Explore Trending AI Robots to see which automated strategies are currently performing best across the market.
Opening Summary
Azenta, Inc. (AZTA), a Burlington, Massachusetts-based provider of life sciences solutions spanning cold-chain sample management and multiomics services, surged in Wednesday's session. Shares climbed about 19.05% to roughly $48.19, well above the previous session's close of $40.48. The rally was driven by better-than-expected fiscal fourth-quarter results and an upbeat outlook for fiscal 2027, delivered after Tuesday's closing bell and reinforced during Wednesday's regular trading.
Earnings Results and Guidance Beat
The stock's upward move was powered by a clean beat on both the top and bottom lines. For the fiscal fourth quarter ended September 30, 2026, Azenta reported revenue of $167.1 million, up 5% year over year and ahead of the roughly $160 million analysts had expected. Adjusted earnings per share came in at $0.28, more than double the consensus estimate of about $0.11 to $0.12, marking one of the company's strongest adjusted per-share results in years.
Just as important for the market reaction, management issued fiscal 2027 revenue guidance of $648 million to $660 million, above the consensus of roughly $639 million, with organic revenue growth projected at 3% to 5% and adjusted EBITDA margin expected to expand. The combination of a surprise earnings beat and forward guidance above Street expectations gave investors a clear reason to reprice AZTA shares sharply higher.
Segment Strength and Strategic Investments
Under the surface, the quarter showed momentum in Azenta's Sample Management Solutions business, which posted revenue of $94 million, up 9% year over year, supported by growth in higher-margin recurring areas such as biorepositories and consumables and instruments. The Multiomics segment, operating under the GENEWIZ brand, generated $73 million as management continued to refocus the business toward gene synthesis and higher-growth sequencing services.
Investors also weighed the company's recent strategic moves in gene synthesis, including technology and supply agreements with Elegen and the acquisition of synthetic biology firm SynPlexity, both aimed at expanding Azenta's presence in AI-enabled drug discovery. These steps reinforced the narrative that the company is repositioning Multiomics as a longer-term growth engine, contributing to the bullish tone around the stock.
Market Context and Trading Activity
The post-earnings reaction drove a gap higher in AZTA, lifting the stock well beyond the roughly $36.98 to $41.28 trading range seen over the prior week and clearing recent resistance levels. Trading interest was elevated relative to the prior sessions, which had averaged roughly 315,000 to 417,000 shares daily, as earnings-related volume and repositioning swept through the name.
The move reflected company-specific momentum rather than broad index strength, as the gap was tied directly to the quarterly report and guidance. Within the life sciences tools and services space, the beat reinforced a more favorable view of turnaround stories showing sequential operational improvement.
What Comes Next for AZTA
Attention now shifts to whether AZTA can sustain its momentum. Investors will watch the first-quarter fiscal 2027 results for confirmation that booking trends and commercial execution continue to improve, and that the Multiomics transition toward gene synthesis delivers on its promise. Margin expansion, free cash flow generation, and the pace of the share repurchase program remain key focal points.
Risks include the company's still-modest GAAP profitability, a substantial full-year impairment-driven net loss, and the possibility that constrained customer capital spending pressures the automated stores business. As with any earnings-driven rally, the stock may remain volatile as analysts update their models and the market digests the new guidance.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a way to compare automated approaches. Explore the page to see which strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZTA in upward trend: price rose above 50-day moving average on October 19, 2026
AZTA moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AZTA as a result. In 60 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for AZTA just turned positive on November 09, 2026. Looking at past instances where AZTA's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +9.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in 214 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 130 of 177 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZTA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AZTA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.136) is normal, around the industry mean (4.964). P/E Ratio (-14.558) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (4.143). Dividend Yield (0.010) settles around the average of (0.005) among similar stocks. P/S Ratio (2.485) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther
Advertisement